Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil

Autor(es):Mostrar menos -

Estofolete, Cassia F. ^{[1, 2]} ; Banho, Cecilia A. ^[2] ; Campos, Guilherme R. F. ^[2] ; Marques, Beatriz de C. ^[2] ; Sacchetto, Livia ^[2] ; Ullmann, Leila S. ^[3] ; Possebon, Fabio S. ^[3] ; Machado, Luana F. ^[1] ; Syrio, Juliana D. ^[1] ; Araujo Junior, Joao P. ^[3] ; Bittar, Cintia ^[4] ; Rahal, Paula ^[4] ; Lobo, Suzana M. A. ^[1] ; Ferreira, Helena Lage ^[5] ; Vasilakis, Nikos ^{[6, 7, 8, 9, 10]} ; Nogueira, Mauricio L. ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Hosp Base, BR-15090000 Sao Jose Do Rio Preto, SP - Brazil

^[2] Med Sch Sao Jose do Rio Preto FAMERP, Lab Pesquisas Virol LPV, BR-15090000 Sao Jose Do Rio Preto, SP - Brazil

^[3] Sao Paulo State Univ UNESP, Biotecnol Inst, BR-18607440 Botucatu, SP - Brazil

^[4] Sao Paulo State Univ UNESP, Intitute Biosci Languages & Exact Sci, BR-15054000 Sao Jose Do Rio Preto, SP - Brazil

^[5] Univ Sao Paulo, Dept Vet Med FZEA USP, BR-13635900 Pirassununga, SP - Brazil

^[6] Univ Texas Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77555 - USA

^[7] Univ Texas Med Branch, Ctr Biodef & Emerging Infect Dis, 301 Univ Blvd, Galveston, TX 77555 - USA

^[8] Univ Texas Med Branch, Ctr Trop Dis, 301 Univ Blvd, Galveston, TX 77555 - USA

^[9] Univ Texas Med Branch, Inst Human Infect & Immun, 301 Univ Blvd, Galveston, TX 77555 - USA

^[10] Univ Texas Med Branch, Sealy Ctr Vector Borne & Zoonot Dis, 301 Univ Blvd, Galveston, TX 77555 - USA

• Tipo de documento: Artigo Científico
• Fonte: Viruses-Basel; v. 13, n. 7 JUL 2021.
• Citações Web of Science: 0

Resumo

The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons. (AU)

• Processo FAPESP: 20/04836-0 - Estudo clínico e epidemiológico de SARS-CoV-2 em uma coorte prospectiva populacional e hospitalar em São José do Rio Preto, São Paulo, Brasil, durante pandemia de 2020
• Beneficiário: Maurício Lacerda Nogueira
• Modalidade de apoio: Auxílio à Pesquisa - Regular